ImmVirX

We're pleased to announce the presentation of new clinical and translational data for our lead candidate IVX037, alongside new preclinical data for our second program IVX055, at the AACR Annual Meeting 2026 in San Diego: buff.ly/yHxIN6q

We're pleased to share that CEO & Co-Founder Dr Malcolm McColl will present at the @NWRcomms Virtual Healthcare Conference on Wednesday, 25 March, at 10:30am AEDT. Interested parties are invited to register for the event at: buff.ly/Jomqx4r

Our team will be presenting two posters at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 17-22 in San Diego: buff.ly/L1bCTuh

We're pleased to share that we have entered into a clinical supply agreement with BeOne Medicines AG to evaluate a combination therapy of our investigational oncolytic virus IVX055 with tislelizumab, BeOne’s PD-1 inhibitor: buff.ly/eM4YxlC

Our Co-Founder and CSO Dr Darren Shafren recently presented an update on ImmVirX's clinical trial progress and future plans at the Bell Potter Securities Healthcare Conference. Click here to view the presentation replay: buff.ly/XAYxmEU

ImmVirX has presented promising clinical data on IVX037 at ESMO 2025, highlighting its activity in MSS-CRC and ovarian cancer: buff.ly/i7ixK4Y Disease control was observed in several MSS-CRC patients with liver metastases, especially those harbouring KRAS/BRAF mutations.

CEO Dr Malcolm McColl presented at the Bioshares Biotech Summit in Hobart today as part of the "Emerging Private Companies & IPOs” session, providing an overview of the Company’s novel oncolytic immunotherapies, including its lead asset IVX037. #Immunotherapy #Biotech #Oncology

We are pleased to report on progress in our Phase 1a/b clinical study and preclinical development of our second asset, being presented at the American Association for Cancer Research (AACR) Annual Meeting in Chicago: buff.ly/VJDuBAB

ImmVirX has expanded its clinical trial collaboration & supply agreement with Innovent into Hepatocellular Carcinoma, the most prevalent form of liver cancer: buff.ly/mulmKzp The companies will evaluate a combination therapy consisting of IVX037 & Innovent’s TYVYT®.

We are pleased to advise that a recording of CEO & Co-Founder Dr Malcolm McColl's presentation at last week's @NWRComms Virtual Healthcare Conference is now available. Shareholders, investors and interested parties can view the recording by clicking here: buff.ly/gK97ijw

ImmVirX will present two posters at the American Association for Cancer Research (@AACR) Annual Meeting 2025, taking place April 25 - 30, 2025 in Chicago: buff.ly/x9aLNFn

Pleased to have our Medical Director Oksana Zdanska present at #ANZBiologicsFestival2025 last week. A great opportunity to put our story in front of a diverse audience of industry experts, thought leaders, and innovators.

ImmVirX has received a ~$5m Research and Development (R&D) tax refund as part of the Australian Government’s R&D tax incentive programme: buff.ly/3WkfdyQ The program encourages companies to invest in R&D activities by providing a refundable tax offset of up to 48.5%.

CEO Dr Malcolm McColl joined the Phase III podcast to discuss ImmVirX’s oncolytic virus platform and its lead asset IVX037. Dr McColl describes IVX037’s mode of action, encouraging early clinical data and interest from pharma groups Listen at: buff.ly/4fkiHsU

ImmVirX today announced that the first 2 patients have been dosed in its CP-IVX001 Phase 1b trial: buff.ly/3AeZY2t The trial will evaluate IVX037 & Innovent Bio’s anti-PD-1 inhibitor TYVYT® (sintilimab) in patients with late stage colorectal, gastric and ovarian cancer.

In addition, we were fortunate to be joined by two clinicians overseeing the trial, Dr Mark Wong and Dr Rafid Al-Asady, to hear their perspectives. We would like to thank them, Cicada Innovations and all who attended the event.

ImmVirX hosted an investor/clinician presentation event at Western Sydney University. Our CEO Dr Malcolm McColl & CSO Prof Darren Shafren presented on our lead drug candidate IVX037, including promising Phase 1 Data, next steps, site expansion plans & upcoming catalysts.

ImmVirX has presented an update showing promising signals in its Phase 1a/b study targeting solid cancers at the MOGA Annual Meeting. IVX037 has been well tolerated, with signs of monotherapy activity, particularly in late-stage colorectal cancer patients: buff.ly/3Mac4Mw

We are pleased to announce the appointment of Dr Oksana Zdanska as Medical Director, commencing today: buff.ly/49y35hH Dr. Zdanska is a highly regarded clinical leader with extensive experience in clinical trials, including drug development of novel treatments.

We are pleased to share a replay of CEO & Acting Chairman Dr Malcolm McColl's presentation at the NWR Virtual Healthcare Conference. Shareholders and other interested parties can view the presentation at: buff.ly/3PLzXfE